

Expected major R&D *milestones* in 2023

		<i>H1 2023</i>	<i>H2 2023</i>
Dupixent®	COPD	Pivotal trial readout (BOREAS)	
	CIndU	Pivotal trial readout	
Oncology	Sarclisa® (1L MM)		Pivotal trial readout (IMROZ)
	tusamitamab ravtansine (2/3L NSCLC)		Interim Analysis (LC03, event-driven)
Neurology	tolebrutinib		GEMINI 1/2 readouts (event-driven)
Rare Blood Disorders	fitusiran (Hem A/B)		Pivotal trial readout
	Altuviiiio™ (Hem A)	U.S. Approval	
Vaccines	Beyfortus®	U.S. Approval	